BioLineRx (BLRX) Non Operating Income (2013 - 2025)

BioLineRx's Non Operating Income history runs 13 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• On a quarterly basis, Non Operating Income fell 79.06% year-over-year to $1.1 million in Q4 2025; TTM through Dec 2025 was $8.1 million, a 56.19% decrease from a year earlier, with the FY2025 full-year figure at $8.1 million, down 56.19% from the prior year.
• Non Operating Income declined to $1.1 million in Q4 2025 per BLRX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Non Operating Income topped out at $7.8 million in Q2 2024 and bottomed at -$7.7 million in Q2 2023.
• The 5-year median for Non Operating Income is $941500.0 (2024), against an average of $976650.0.
• Across the five-year window, Non Operating Income surged 311.06% in 2022 and slumped 1788.43% in 2023, its largest moves.
• Year by year, Non Operating Income stood at $2.2 million in 2021, then soared by 58.85% to $3.6 million in 2022, then fell by 16.43% to $3.0 million in 2023, then soared by 81.15% to $5.4 million in 2024, then sank by 79.06% to $1.1 million in 2025.
• Per Business Quant, the three latest BLRX Non Operating Income figures stand at $1.1 million (Q4 2025), $1.2 million (Q3 2025), and -$1.9 million (Q2 2025).